Document is current

Article History

Received: 18 January 2024

Accepted: 30 November 2024

First Online: 18 December 2024

Declarations

:

: This study was approved by the Ethical Committee of the First Affiliated Hospital of Sun Yat-sen University. The central ethics committee has approved our study for the various centers. This study was registered with the Chinese Clinical Trials Registry (, ID: ChiCTR2000038877). We will obtain informed consent from all participants in the study, and they must be signed by the guardian and must include a date. The signed informed consent form will be kept independently by researchers and participants, and the former will be made available to project managers for monitoring and inspection. The consent form provided to participants includes provisions for the possible use of their data and biological specimens in ancillary studies. Specifically, we will collect and store approximately 2 ml of residual sample from the patient’s bone marrow tests. In the event of a relapse, we may test the leukemia cells for unknown genetic markers that could impact treatment efficacy or cause relapse. Participants are informed that their willingness to contribute data for future research is entirely voluntary, and they are under no obligation to consent to any studies beyond the scope of this one.In the course of the clinical study, any modification to the study protocol and other relevant documents shall be submitted to the ethics committee for further approval and can only be implemented with the consent of the ethics committee.

: Not applicable. This manuscript does not include any personal information.

: The authors declare no competing interests.